|1.||Carminati, Paolo: 2 articles (09/2005 - 08/2005)|
|2.||Serlupi-Crescenzi, Ottaviano: 2 articles (09/2005 - 08/2005)|
|3.||De Santis, Rita: 2 articles (09/2005 - 08/2005)|
|4.||Tassone, Pierfrancesco: 2 articles (06/2005 - 10/2002)|
|5.||Venuta, Salvatore: 2 articles (06/2005 - 10/2002)|
|6.||Tagliaferri, Pierosandro: 2 articles (06/2005 - 10/2002)|
|7.||Arseni, Brunilde: 1 article (09/2005)|
|8.||Campo, Silvia: 1 article (09/2005)|
|9.||Cherubini, G: 1 article (09/2005)|
|10.||Salone, B: 1 article (09/2005)|
05/01/1997 - "On the basis of these results we propose the super-antagonist Sant7 as a possible candidate for the immunotherapy of multiple myeloma."
06/01/2005 - "Gene expression profiling of INA-6 cells showed down-regulation of proliferation/maintenance and cell cycle control genes, as well as up-regulation of apoptotic genes in multiple myeloma cells triggered by Sant7 and dexamethasone combination. "
09/01/2001 - "The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells."
06/01/2005 - "Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma."
06/01/2005 - "Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma."
|3.||B-Cell Lymphoma (Lymphoma, B Cell)
09/07/2005 - "Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma."
09/07/2005 - "This work describes the effects of the recombinant or adenovirally-delivered IL-6 superantagonist Sant7, anti-IL-6 and IL-6 receptor monoclonal antibodies in a severe murine model of human B-cell lymphoma induced in SCID mice by transplantation of an LCL-41 cell line variant (isotype-switched IgM>IgG). "
|4.||Lymphoproliferative Disorders (Lymphoproliferative Disorder)
|1.||Interleukin-6 (Interleukin 6)
|3.||Interleukin-6 Receptors (Interleukin 6 Receptor)
|5.||Immunoglobulin M (IgM)
|6.||Immunoglobulin G (IgG)
|8.||zoledronic acid (zoledronate)
|1.||Transplantation (Transplant Recipients)